Literature DB >> 18289811

Freeze drying of peptide drugs self-associated with long-circulating, biocompatible and biodegradable sterically stabilized phospholipid nanomicelles.

Sok Bee Lim1, Israel Rubinstein, Hayat Onyüksel.   

Abstract

The purpose of this study was to determine optimal lipid concentration range for lyophilization of sterically stabilized phospholipid nanomicelles (SSM) and the freeze drying feasibility of self-associated therapeutic peptide-SSM assemblies. SSM at 5-20 mM 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000) (DSPE-PEG(2000)) were analyzed for particle size and viscosity before and after freeze drying which showed no significant changes (p>0.05). However, a steep increase in viscosity was seen for SSM above 15 mM phospholipid implying micelle-micelle interaction. Greater shrinkage of lyophilized cakes was observed below 10 mM phospholipid while they were more fibrous above 15 mM. Therefore, 10-15 mM DSPE-PEG(2000) was chosen as the optimal phospholipid concentration for lyophilized SSM. When vasoactive intestinal peptide (VIP), glucagon-like peptide 1 (GLP-1) or gastric inhibitory peptide (GIP) (each, 67 microM) was added to SSM (10mM), formulations showed no significant change in particle size, peptide fluorescence and peptide alpha-helicity before and after lyophilization. In conclusion, we found that peptide drug-SSM interactions are conserved during lyophilization.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18289811      PMCID: PMC2413132          DOI: 10.1016/j.ijpharm.2008.01.014

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  17 in total

Review 1.  Proprietary Rel-Ease drug delivery technology: opportunity for sustained delivery of peptides, proteins and small molecules.

Authors:  Ming Ye; Gajanan Bhat; Kevin A Johnston; Heow Tan; Marc Garnick
Journal:  Expert Opin Drug Deliv       Date:  2006-09       Impact factor: 6.648

2.  Human VIP-alpha: a long-acting, biocompatible and biodegradable peptide nanomedicine for essential hypertension.

Authors:  Hayat Onyüksel; Florence Séjourné; Hideyuki Suzuki; Israel Rubinstein
Journal:  Peptides       Date:  2006-04-18       Impact factor: 3.750

Review 3.  Drug delivery into the brain using poly(lactide-co-glycolide) microspheres.

Authors:  Philippe Menei; Claudia Montero-Menei; Marie-Claire Venier; Jean-Pierre Benoit
Journal:  Expert Opin Drug Deliv       Date:  2005-03       Impact factor: 6.648

Review 4.  Interactions of VIP, secretin and PACAP(1-38) with phospholipids: a biological paradox revisited.

Authors:  A Krishnadas; H Onyüksel; I Rubinstein
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

5.  Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

Authors:  M A Nauck; U Niedereichholz; R Ettler; J J Holst; C Orskov; R Ritzel; W H Schmiegel
Journal:  Am J Physiol       Date:  1997-11

Review 6.  Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes.

Authors:  J F Gautier; S Fetita; E Sobngwi; C Salaün-Martin
Journal:  Diabetes Metab       Date:  2005-06       Impact factor: 6.041

7.  Poly(pro)II helices in globular proteins: identification and circular dichroic analysis.

Authors:  N Sreerama; R W Woody
Journal:  Biochemistry       Date:  1994-08-23       Impact factor: 3.162

8.  Phospholipids modulate the biophysical properties and vasoactivity of PACAP-(1--38).

Authors:  Takaya Tsueshita; Salil Gandhi; Hayat Onyüksel; Israel Rubinstein
Journal:  J Appl Physiol (1985)       Date:  2002-10

9.  A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo.

Authors:  H Onyüksel; H Ikezaki; M Patel; X P Gao; I Rubinstein
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

Review 10.  Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors.

Authors:  David A Groneberg; Klaus F Rabe; Axel Fischer
Journal:  Eur J Pharmacol       Date:  2006-02-10       Impact factor: 4.432

View more
  22 in total

1.  Protected graft copolymer excipient leads to a higher acute maximum tolerated dose and extends residence time of vasoactive intestinal Peptide significantly better than sterically stabilized micelles.

Authors:  Sandra Reichstetter; Gerardo M Castillo; Israel Rubinstein; Akiko Nishimoto-Ashfield; Manshun Lai; Cynthia C Jones; Aryamitra A Banerjee; Aryamitra Banjeree; Alex Lyubimov; Duane C Bloedow; Alexei Bogdanov; Elijah M Bolotin
Journal:  Pharm Res       Date:  2012-12-07       Impact factor: 4.200

2.  Human pancreatic polypeptide in a phospholipid-based micellar formulation.

Authors:  Amrita Banerjee; Hayat Onyuksel
Journal:  Pharm Res       Date:  2012-03-08       Impact factor: 4.200

3.  A novel peptide nanomedicine against acute lung injury: GLP-1 in phospholipid micelles.

Authors:  Sok Bee Lim; Israel Rubinstein; Ruxana T Sadikot; James E Artwohl; Hayat Önyüksel
Journal:  Pharm Res       Date:  2010-11-25       Impact factor: 4.200

4.  Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer.

Authors:  Hacer Cesur; Israel Rubinstein; Ashwini Pai; Hayat Onyüksel
Journal:  Nanomedicine       Date:  2008-12-13       Impact factor: 5.307

5.  Curcumin in VIP-targeted sterically stabilized phospholipid nanomicelles: a novel therapeutic approach for breast cancer and breast cancer stem cells.

Authors:  Ece Gülçür; Mentor Thaqi; Fatima Khaja; Antonina Kuzmis; Hayat Önyüksel
Journal:  Drug Deliv Transl Res       Date:  2013-12       Impact factor: 4.617

6.  Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis.

Authors:  Varun Sethi; Israel Rubinstein; Antonina Kuzmis; Helen Kastrissios; James Artwohl; Hayat Onyuksel
Journal:  Mol Pharm       Date:  2013-01-23       Impact factor: 4.939

7.  A new lipid-based nano formulation of vinorelbine.

Authors:  Fatemeh Bahadori; Gülaçtı Topçu; Mehmet S Eroğlu; Hayat Onyüksel
Journal:  AAPS PharmSciTech       Date:  2014-05-29       Impact factor: 3.246

8.  Recent developments in protein and peptide parenteral delivery approaches.

Authors:  Ashaben Patel; Kishore Cholkar; Ashim K Mitra
Journal:  Ther Deliv       Date:  2014-03

9.  Vasoactive Intestinal Peptide Nanomedicine for the Management of Inflammatory Bowel Disease.

Authors:  Dulari Jayawardena; Arivarasu N Anbazhagan; Grace Guzman; Pradeep K Dudeja; Hayat Onyuksel
Journal:  Mol Pharm       Date:  2017-10-19       Impact factor: 4.939

10.  Colonic delivery of vasoactive intestinal peptide nanomedicine alleviates colitis and shows promise as an oral capsule.

Authors:  Shubha Priyamvada; Anoop Kumar; Seema Saksena; Hayat Onyuksel
Journal:  Nanomedicine (Lond)       Date:  2020-09-25       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.